Alphatec Holdings, Inc. (NASDAQ:ATEC) Short Interest Update

Alphatec Holdings, Inc. (NASDAQ:ATEC) experienced a noteworthy decline in short interest during November. As of November 15th, the total short interest stood at 10,590,000 shares, which represents a decrease of 10.3% compared to the 11,810,000 shares recorded on October 31st. With an average daily trading volume of 2,260,000 shares, the current days-to-cover ratio is 4.7 days.

Alphatec Stock Performance

On Friday, NASDAQ ATEC opened at $10.48. The company’s debt-to-equity ratio is at 30.21, alongside a quick ratio of 1.15 and a current ratio of 2.32. The fifty-day moving average price of the stock is $7.11, while its two-hundred-day moving average is $8.20. Alphatec boasts a market capitalization of $1.49 billion, a price-to-earnings ratio of -8.19, and a beta value of 1.31. Throughout the last year, the stock has seen a low of $4.88 and a high of $17.34.

Institutional Inflows and Outflows

Recently, several institutional investors and hedge funds have adjusted their stakes in Alphatec Holdings. Comerica Bank notably increased its stake by 64.8% in the first quarter, acquiring an additional 2,534 shares to own a total of 6,443 shares valued at $89,000. During the second quarter, Van ECK Associates Corp raised its position in Alphatec by 11.8%, buying 1,300 additional shares for a new total of 12,275 shares, estimated at $128,000. In the third quarter, XTX Topco Ltd entered the scene by purchasing a new stake valued at around $69,000. Furthermore, Cetera Advisors LLC raised its holdings in Alphatec by 15.6% in the first quarter, owning 12,720 shares now worth $175,000 after acquiring an extra 1,720 shares. Lastly, Net Worth Advisory Group also bought a new position in the company during the third quarter at about $76,000. Currently, institutional investors and hedge funds own approximately 66.35% of Alphatec's stock.

Wall Street Analyst Opinions

In recent reports, analysts have expressed varied opinions regarding Alphatec Holdings. Lake Street Capital reduced its price target from $32.00 to $18.00 while maintaining a "buy" rating on the stock as of September 3rd. HC Wainwright reiterated its "buy" rating and set a $20.00 price target in a report dated October 31st. Needham & Company LLC also reissued a "buy" rating, assigning a $13.00 target price on the same date. Canaccord Genuity Group reaffirmed its "buy" rating and a price target of $20.00 in late August. Barclays recently raised its price objective from $19.00 to $20.00, granting the company an "overweight" rating on November 19th. There is one analyst with a hold rating and eight analysts who have assigned a buy rating to Alphatec. According to data compiled by MarketBeat.com, the company holds an average rating of "Moderate Buy," along with a consensus price target of $17.11.

Overview of Alphatec

About Alphatec

Alphatec Holdings, Inc. is a medical technology firm dedicated to designing, developing, and enhancing technologies for the surgical treatment of spinal disorders, both in the U.S. and abroad. The company produces and markets implants and instruments, primarily through third-party suppliers. Its product lineup includes innovations such as the Alpha InformatiX product platform, featuring the EOS imaging system for full-body imaging, the VEA alignment mobile application for rapid alignment assessment, SafeOp Neural InformatiX System for advanced nerve monitoring, and the Valence intra-operative system, which combines navigation and robotics for spinal surgeries.

Alphatec, Stocks, ShortInterest